Tissue engineering refers to the process of combining scaffolds, cells, and/or biologically active molecules for the production of functional tissues. The potential to assemble functional constructs that restore, maintain, or improve damaged tissues or organs offer exciting prospects for changing traditional approaches to clinical treatment. The wide range of organs that present as strong candidates for engineering reconstruction – bone, cartilage, liver, pancreas, skin, blood vessel, and more – enables the field to meet critical health care needs and potentially treat a variety of diseases.
While tissue engineering has a broad definition and applications, the fundamental research and comprehensive clinical trial evaluations that will be required provide a significant need for the establishment of harmonized standards. There is an acute need for identification and assessment of leading technologies that have successfully come to market, and to extract insights from their manufacturers’ experience. The SCB is equipped to conduct this assessment and implement subsequent projects that guide consensus standards development and reference guidelines, with the ultimate goal of informing the global tissue engineering market with our initiatives. Elena Kfoury and Dr. Jason Wertheim lead the Tissue Engineering sector, with a comprehensive expertise in clinical, research, and industry perspectives.
Elena Kfoury, Axiogenesis
Dr. Jason Wertheim, Northwestern